<DOC>
	<DOCNO>NCT00003335</DOCNO>
	<brief_summary>RATIONALE : Umbilical cord blood transplantation may allow doctor give high dos chemotherapy radiation therapy kill cancer cell . PURPOSE : This phase II trial study allogeneic umbilical cord blood transplantation see well work give chemotherapy radiation therapy treat patient high-risk hematologic cancer .</brief_summary>
	<brief_title>Umbilical Cord Blood Transplantation Treating Patients With High-Risk Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine rate hematologic immune reconstitution patient high risk hematologic malignancy undergo high dose chemoradiotherapy follow unrelated umbilical cord blood ( UCB ) transplantation . - Determine incidence graft-versus-host-disease setting . - Describe incidence recurrent disease patient post UCB transplant . - Describe incidence serious infection secondary lymphoproliferative disease follow transplantation UCB patient . - Determine specifically whether large recipient durably engraft unrelated UCB , determine whether nucleate cell progenitor cell content graft predictive hematological engraftment . OUTLINE : Patients may undergo back-up peripheral blood stem cell collection prior treatment . Patients receive 9 fraction total body irradiation ( TBI ) day -9 -5 follow melphalan IV three day day -4 -2 antithymocyte globulin IV methylprednisolone IV three day day -3 -1 . On day 0 , patient receive umbilical cord blood infusion . If TBI tolerate , busulfan substitute administer orally every 6 hour 4 day day -8 -5 . Cyclosporine methylprednisolone begin day -2 continue 6 month . Patients follow least monthly 1 year , every 6 month second year , annually thereafter . PROJECTED ACCRUAL : There maximum 48 patient accrue study 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm high risk malignancy include : Acute nonlymphocytic leukemia ( ANLL ) induction failure , first complete remission high risk feature include stem cell biphenotypic classification ( acute myeloid leukemia ( AML ) M0 ) , erythroleukemia ( AML M6 ) , acute megakaryocytic leukemia ( AML M7 ) , cytogenic marker indicative poor prognosis , failure achieve complete remission standard induction therapy Acute lymphocytic leukemia ( ALL ) ANLL second subsequent remission Chronic myeloid leukemia ( CML ) chronic phase CML accelerate phase blast crisis eligible reinduction chemotherapy convert disease chronic phase High risk ALL first complete remission Myelodysplastic syndrome evidence evolution acute myeloid leukemia Refractory anemia excess blast Refractory anemia excess blast transformation NonHodgkin 's lymphoma ( NHL ) , ANLL , ALL recurrent disease autologous stem cell transplantation Must also meet following condition : No HLAABC/DR identical relate bone marrow UCB donor No 5/6 antigen match related bone marrow UCB donor Condition preclude wait search find donor National Marrow Donor Registry Must available serologic match umbilical cord blood unit New York Blood Center 's Placental Blood Project No active CNS disease PATIENT CHARACTERISTICS : Age : Under 55 time umbilical cord blood transplantation Performance status : Zubrod 01 Karnofsky 80100 % Life expectancy : At least 3 month Hematopoietic : For patient ALL ANLL remission , CML chronic phase , NHL without marrow involvement elect undergo autologous peripheral blood stem cell collection storage : WBC least 3,000/mm^3 Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL ALT/AST great 4 time normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : Normal cardiac function echocardiogram radionuclide scan ( shorten fraction ejection fraction least 80 % normal value age ) Pulmonary : FVC FEV_1 least 60 % predicted age For adult : DLCO least 60 % predict Other : HIV negative No active infection time autologous stem cell harvest pretransplant cytoreduction Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Prior autologous stem cell transplantation allow Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>